Board of Directors

Kira Sheinerman, Ph.D., MBA
Chairperson of the Executive Committee

Kira Sheinerman is a Director, Healthcare Investment Banking at Rodman & Renshaw. Dr. Sheinerman joined Rodman & Renshaw in April of 2005 as a Vice President, Investment Banking. While at Rodman & Renshaw, she lead or participated in 37 financial and strategic transactions valued in excess of $1.0 billion and ranging in size from $4 million to $100 million. Prior to her current position at Rodman & Renshaw, she worked at The Arcus Group, specializing in analysis of market opportunities for early to late stage biotech products and in investment and acquisition opportunities in the fields of oncology, CNS, infectious diseases and critical care; she also served as a business development consultant for a number of early stage biotech companies. Dr. Sheinerman received a Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine for her work on molecular mechanisms of Alzheimer's disease. She also holds a MBA from the Honors program at Baruch College/CUNY.

David Sidransky, M.D.
Member of the Executive Committee

Dr. Sidransky is a founder of several private biotechnology companies and has served on numerous scientific advisory boards of many private and public companies, including Medimmune, Telik, Roche and Amgen. He was formerly on the board of scientific counselors at the NIDCR and a member of the Recombinant DNA advisory committee at the National Institute of Health NIH (RAC). He currently serves on the Board of Directors of ImClone Systems and as ViceChairman at Alfacell, and Chairman at Champions Biotechnology. Dr. Sidransky is on numerous editorial boards and has served as senior editor of several cancer related journals. Currently, Dr. Sidransky is the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine. In addition, he is Professor of Oncology, Otolaryngology-Head and Neck Surgery, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital. Dr. Sidransky is certified in Internal Medicine and Medical Oncology by the American Board of Medicine. He has over 350 peer-reviewed publications, and has contributed more than 60 cancer reviews and chapters and also has numerous issued biotechnology patents. He has been the recipient of many awards and honors, including the 1997 Sarstedt International prize from the German Society of Clinical Chemistry, 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians and the 2004 Hinda Rosenthal Award by the American Association of Cancer Research.

Gian Luigi Longinotti-Buitoni, Ph.D.
Chairman

Dr. Buitoni joined Xenomics Inc. as Executive Chairman on November 14, 2006. Since 2004, Dr. Buitoni has been Chief Executive Officer of Goal.com, an international new media company focused on sports, particularly soccer. From 2000 to 2003, Dr. Buitoni was President and Chief Executive Officer of Polo Europe, a division of Polo Ralph Lauren. From 1992 to 2000, Dr. Buitoni was Chief Executive Officer of Ferrari North America.

John P. Brancaccio
Director

John Brancaccio was appointed to the Xenomics, Inc. Board of Directors in January 2006. Mr. Brancaccio has been the chief financial officer of Accelerated Technologies, Inc., an incubator for venture backed medical device companies. He also serves on the boards of Callisto Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc. and Alfacell Corp., all of which are publicly traded biopharmaceutical companies where he serves on their respective Audit and Compensation Committees. He was the secretary and treasurer of Memory Pharmaceuticals Corporation from December 2003 to March 2004 after serving in the capacity of their acting chief financial officer from May 2002 to December 2003. Prior to Memory Pharmaceuticals, Mr. Brancaccio held the positions of chief financial officer and chief operating officer of Eline Group, a publicly traded entertainment and media company, where he oversaw the roll up of several related companies into the group and completed private equity financing placements. Prior to joining Eline Group, he held a number of senior executive positions in public and private companies including Atlantic Pharmaceuticals, Zambon Corporation, Deven International and Health Learning Systems. During his tenure with these companies he participated in initial public offerings and the negotiating of licensing and development agreements within both the pharmaceutical and biotechnology industries. He is a retired Certified Public Accountant and a graduate of Seton Hall University.

Donald H. Picker, Ph.D.
Director

Dr. Picker was appointed a director of the Company on July 2, 2004. From January 2007 to October 2007, he served as the President of Tapestry Pharmaceuticals, Inc. He served as Executive Vice President, R&D of Callisto Pharmaceuticals, Inc. from April 2004 through December 2006. From May 2003 until April 2004, Dr. Picker served as Senior Vice President, Drug Development of Callisto. Dr. Picker was Chief Executive Officer and President of Synergy Pharmaceuticals Inc. and a member of its board of directors from 1998 to April 2003. From 1996 to 1998, Dr. Picker was President and Chief Operating Officer of LXR Biotechnology Inc. From 1991 to 1996, he was Senior Vice President of Research and Development at Genta Inc.

Abba David Poliakoff
Director

Abba David Poliakoff is a member of the law firm of Gordon, Feinblatt, Rothman, Hoffberger & Hollander, LLC, in Baltimore, Maryland, Chairman of the Firm's Business Department, and a Member of the Firm's Electronic Discovery Practice Group. Mr. Poliakoff received his J.D. degree, magna cum laude, in 1977 from the University of Baltimore Law School, where he was an editor of the University of Baltimore Law Review and Associate Editor of The Forum Law Journal. After law school, Mr. Poliakoff joined the staff of the U.S. Securities and Exchange Commission in Washington, D.C., where he became a senior attorney in the Division of Corporation Finance. Mr. Poliakoff is currently a member of the Maryland State Bar Association's Business Law Section and former Chair of its Committee on Securities. Formerly he was a member of the Business Regulations Article Review Committee of the Committee to Revise the Maryland Annotated Code. He has been listed in Chambers USA, Leading Business Lawyers since its inception in 2003. Mr. Poliakoff is a member of the Board of Directors of the Greater Baltimore Technology Council (GBTC) and Chair of its Legislative Committee. He is a former Chair of the Maryland Business & Technology Coalition, member of the Technology Council of Maryland, and member of the MIT Enterprise Forum. Mr. Poliakoff is currently the Chairman of the Maryland Israel Development Center, a joint venture between the State of Israel and the State of Maryland collaborating through the Maryland Department of Business and Economic Development and the Israeli Ministry of Industry and Trade.